Why BGPT?
logo

Check Claims Before You Publish

See how your reported results read as versioned evidence records — linked to experiments and limitations.Know what the science actually supports before you trust the answer.

Press Enter ↵ to review claims



    Explore by Goal












     Quick Explanation


    Karel Souček — scientific strength snapshot
    • Evidence profile: strong focus on cancer cell-state regulation (e.g., miRNA regulation, EMT/therapy resistance), with some breadth into cell physiology and experimental methods.
    • Support quality (based on author’s cited works in your prompt): several highly cited reviews and cell-based studies, but review-type evidence is inherently limited for causal claims.
    • Key critique: without full-text access to the listed individual primary papers, I can’t verify the exact experimental rigor, effect sizes, controls, and reproducibility details.



     Long Explanation


    Author Review: Karel Souček
    This review is skeptical and evidence-weighted. I distinguish between: (1) what is clearly supported by specific cited works, (2) what is plausible but not directly evidenced from the excerpt-level information provided, and (3) what remains unknown without primary-method details.
    1) Citation footprint (from your OpenAlex snapshot)
    Your provided OpenAlex snapshot lists works_count=285, cited_by_count=4108, and h_index=33 for “Karel Souček”. (These numbers come from the snapshot you provided; I did not re-query OpenAlex here.)
    2) Visualizing how citation attention is distributed over time
    3) What scientific areas are most visible in the provided works list
    4) Evidence-weighted assessment of scientific contributions (from the works explicitly provided)
    4.1 Cancer regulatory biology (miRNA / EMT / resistance)
    • The review “Alternative mechanisms of miR-34a regulation in cancer” (2017) summarizes multiple mechanisms proposed for miR-34a regulation and frames miR-34a as a master regulator with implications for tumor suppression strategies. As a review, it is useful for mapping hypotheses and pathways, but it cannot by itself establish causal effect sizes or directionality in specific cellular contexts.
    • The review “ZEB1: A Critical Regulator of Cell Plasticity, DNA Damage Response, and Therapy Resistance” (2020) synthesizes literature linking ZEB1 with EMT-linked plasticity, DNA damage response, and chemoresistance/therapy resistance. Again, review evidence supports associations and mechanistic frameworks, but not direct causality in any one system unless primary experiments are also provided.
    4.2 Primary experimental work: mechanistic cell biology & biomarkers
    • “Normal and prostate cancer cells display distinct molecular profiles of α-tubulin posttranslational modifications” (2006) indicates work on posttranslational modification patterns of α-tubulin and their relation to structural/functional diversity of microtubules, framed in normal vs prostate cancer cells.
      Critical note: the excerpt-level metadata I received does not specify the experimental platform, sample size, statistical treatment, or whether findings generalize across cell lines/patients.
    • “The fibroblast surface markers FAP, anti-fibroblast, and FSP are expressed by cells of epithelial origin and may be altered during epithelial-to-mesenchymal transition” (2017) argues that commonly used fibroblast markers may not be fibroblast-specific and may be expressed by epithelial-origin cells and altered during EMT.
      Blind spot: without the full methods/results, I can’t assess marker specificity rigor (e.g., gating strategy, controls, validation cohorts).
    4.3 Cell-death / pathway competition framing (apoptosis vs autophagy)
    • “Alternative Pathways of Cancer Cell Death by Rottlerin: Apoptosis versus Autophagy” (2012) is a mechanistic framing that contrasts apoptosis and autophagy as routes of cancer cell death for a compound with reported antiproliferative properties.
      Skeptical lens: evidence-strength is marked weak because the provided description fits an “evidence-based complementary” framing and the citation excerpt alone does not show primary experimental quality (dose ranges, controls, autophagy flux measurement, blinding, etc.).
    5) Scientific citation metrics: what your snapshot implies (and what it can’t)
    Your prompt also provides an additional “Author Citation Information” block: h-index 5, total citations 124, paper count 9 for Karel Souček. That conflicts with the OpenAlex snapshot (h-index 33; citations 4108; works 285). Interpretation: these are likely from different scopes/curations (e.g., one subset of papers you included, or a disambiguation/crawl artifact).
    Scientific quality can’t be reliably inferred from citations alone; high citation counts can reflect broad relevance, review citation behavior, or field-wide growth.
    6) Critical appraisal (rigor, reproducibility risks, and blind spots)
    • Review-heavy evidence in provided list: Several explicitly provided items are reviews (miR-34a regulation; ZEB1; Trop2 review). Reviews are valuable for synthesis, but they can overemphasize consensus narratives and underrepresent null/negative results; causal claims require primary validation.
    • Biomarker specificity risk: The fibroblast marker/EMT caveat paper is exactly the kind of result that can reveal false specificity and experimental misclassification—yet the strength depends on the experimental validation details (controls, orthogonal validation).
    • Context dependence in oncology: Cell-state regulation (EMT/plasticity; PTM landscapes) is often highly context-dependent (cell line, microenvironment, culture conditions). Without direct primary-method detail, I can’t quantify generalizability from the metadata alone.
    What would most change my assessment?
    • Full-text access to the primary experiments behind the provided works list, so I can verify: replication count, statistical rigor, positive/negative controls, and whether results hold across independent models.
    • Whether “highly cited” results include strong mechanistic grounding (e.g., genetic perturbations, rescue experiments) vs predominantly correlative observations.
    7) Quick usability: relevant BGPT deep-div links
    Note on scope limitations
    Your prompt provides a mixture of (a) individual paper titles without DOIs, and (b) some papers with DOIs. I only made mechanistic/claim-level statements where I could cite the provided DOI-based sources. If you want a stronger, truly “scientific strength” review, share the remaining paper DOIs or enable BGPT to pull the full-text methods.


    Feedback:    

    Updated: May 01, 2026

     BGPT Author Review


    Scientific Quality

    60%

    Moderate-to-strong scientific quality suggested by (i) a long publication footprint with substantial citation attention in the provided snapshot, and (ii) at least some mechanistic or methodological relevance (e.g., biomarker specificity during EMT, PTM profiling framing). However, the provided evidence set is incomplete (many listed items lack DOI/full-text), and several explicitly cited items are reviews—useful for synthesis but not strong on their own for causal rigor. Key concerns: context dependence in oncology, need for primary-method scrutiny, and inability here to verify effect sizes/controls/reproducibility from metadata alone.


    Communication Quality

    70%

    The cited works include multiple reviews, which usually require clear conceptual framing. But because only metadata/excerpts are available in your prompt, I can’t judge clarity of experimental presentation (figures/tables, limitations, statistical reporting) from full text.


    Author Novelty

    50%

    Likely contributes incremental mechanistic specificity (e.g., marker specificity confounds; PTM landscape comparisons; regulatory pathway synthesis). From the provided items alone, I can’t confirm breakthrough novelty, because many items are reviews and primary-specific novelty cannot be assessed without methods and results.


    Scientific Rigor

    50%

    Insufficient primary-method detail in the provided dataset prevents high confidence. Where a claim is about specificity/biomarkers or molecular profiling, rigor depends heavily on controls, validation strategy, and replication—unverifiable here. Reviews are intrinsically lower rigor for causal inference.

     Hypothesis Graveyard


    The idea that fibroblast-associated surface markers (FAP/FSP/anti-fibroblast) are universally specific for fibroblasts across EMT states is less favored given evidence that they can be expressed by epithelial-origin cells and altered during EMT.


    The strongman claim that a single pathway (e.g., one death modality like apoptosis) fully explains cancer cell death outcomes for rottlerin-like compounds is less favored because the provided framing contrasts apoptosis versus autophagy pathways; without robust flux/causality evidence, this is unlikely to be universally true.

     Science Art


    Author Review: Karel Souček Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending